In contrast to cutaneous melanoma, UM is characterized by a low response rate to checkpoint inhibitors and absence of druggable mutations in receptor tyrosine kinases, and recent breakthroughs in the treatment of metastatic UM has not been introduced in our clinical routine at St. The gene discussed is NTRK1; the disease is cutaneous melanoma.